• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

重症新型冠状病毒肺炎患者静脉注射免疫球蛋白治疗成功

Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia.

作者信息

Lanza Maurizia, Polistina Giorgio Emanuele, Imitazione Pasquale, Annunziata Anna, Di Spirito Valentina, Novella Carannante, Fiorentino Giuseppe

机构信息

Unit of Respiratory Physiopathology, Monaldi Hospital, Naples, Italy.

First Division Infectious Diseases, Cotugno Hospital, Naples, Italy.

出版信息

IDCases. 2020 May 16;21:e00794. doi: 10.1016/j.idcr.2020.e00794. eCollection 2020.

DOI:10.1016/j.idcr.2020.e00794
PMID:32426229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7229478/
Abstract

We describe a 42-year old woman, admitted to our Department after 15 days of persistence of respiratory failure and treated with infusion of intravenous immunoglobulin with a successful outcome.

摘要

我们描述了一名42岁女性，在呼吸衰竭持续15天后入住我科，并接受静脉注射免疫球蛋白治疗，结果成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/5db0f3292dcf/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/420df9a39d70/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/5ea606bc122c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/5db0f3292dcf/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/420df9a39d70/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/5ea606bc122c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bea/7242864/5db0f3292dcf/gr3.jpg

相似文献

1
Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia.重症新型冠状病毒肺炎患者静脉注射免疫球蛋白治疗成功
IDCases. 2020 May 16;21:e00794. doi: 10.1016/j.idcr.2020.e00794. eCollection 2020.
2
A severe pneumonia inducing an acute antibody-mediated pulmonary graft rejection.一种引发急性抗体介导的肺移植排斥反应的重症肺炎。
Lung India. 2017 Jan-Feb;34(1):85-87. doi: 10.4103/0970-2113.197104.
3
Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.皮质类固醇与静脉注射免疫球蛋白脉冲疗法治疗重度托珠单抗耐药的COVID-19：三例临床病例报告
Cureus. 2020 Jul 7;12(7):e9038. doi: 10.7759/cureus.9038.
4
A 22-year-old woman with fulminant Chlamydia pneumoniae pneumonia.一名患有暴发性肺炎衣原体肺炎的22岁女性。
Fukushima J Med Sci. 2002 Jun;48(1):57-62. doi: 10.5387/fms.48.57.
5
[A case of fulminant Mycoplasma pneumoniae pneumonia despite adequate antibiotic treatment].[一例尽管接受了充分抗生素治疗仍发生的暴发性肺炎支原体肺炎病例]
Nihon Kokyuki Gakkai Zasshi. 2009 Jun;47(6):471-5.
6
Streptococcal toxic shock syndrome in a patient with community-acquired pneumonia. Impact of rapid diagnostics on patient management.一名社区获得性肺炎患者的链球菌中毒性休克综合征。快速诊断对患者管理的影响。
Access Microbiol. 2020 Jun 17;2(8):acmi000144. doi: 10.1099/acmi.0.000144. eCollection 2020.
7
Acute Respiratory Failure Secondary to COVID-19 Viral Pneumonia Managed With Hydroxychloroquine/Azithromycin Treatment.新冠病毒肺炎继发急性呼吸衰竭采用羟氯喹/阿奇霉素治疗
Cureus. 2020 May 25;12(5):e8268. doi: 10.7759/cureus.8268.
8
[Severe chlamydia pneumoniae pneumonia requiring mechanical ventilation and steroid therapy in an elderly patient].[老年患者重症肺炎衣原体肺炎需机械通气及类固醇治疗]
Nihon Ronen Igakkai Zasshi. 2004 Sep;41(5):552-7. doi: 10.3143/geriatrics.41.552.
9
Successful recovery from critical COVID-19 pneumonia with extracorporeal membrane oxygenation: A case report.体外膜肺氧合治疗重症新型冠状病毒肺炎成功康复：一例报告
Respir Med Case Rep. 2020 May 31;30:101113. doi: 10.1016/j.rmcr.2020.101113. eCollection 2020.
10
An adult case of severe life-threatening Mycoplasma pneumoniae pneumonia due to a macrolide-resistant strain, Japan: a case report.日本大环内酯类耐药株致成人严重威胁生命的肺炎支原体肺炎 1 例报告
BMC Infect Dis. 2019 Feb 28;19(1):204. doi: 10.1186/s12879-019-3846-1.

引用本文的文献

1
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.新型冠状病毒肺炎被动免疫治疗的最新进展：基于证据的方法和临床试验。
Int Immunopharmacol. 2022 Aug;109:108786. doi: 10.1016/j.intimp.2022.108786. Epub 2022 Apr 21.
2
Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study.非重症监护环境中低丙种球蛋白血症对 COVID-19 病程的影响：一项单中心回顾性队列研究。
Front Immunol. 2022 Mar 10;13:842643. doi: 10.3389/fimmu.2022.842643. eCollection 2022.
3
The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin.

本文引用的文献

1
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.常规静脉注射免疫球蛋白治疗对新型冠状病毒肺炎（COVID-19）重症肺炎患者预后的影响。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.03.044. Epub 2020 Apr 10.
2
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
3
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.
IgA在富含IgM/IgA的免疫球蛋白制剂Trimodulin中的功能作用。
Biomedicines. 2021 Dec 3;9(12):1828. doi: 10.3390/biomedicines9121828.
4
Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.静脉注射免疫球蛋白在预防和治疗 2019 年冠状病毒疾病中的重要作用。
Scand J Immunol. 2021 Nov;94(5):e13101. doi: 10.1111/sji.13101. Epub 2021 Sep 16.
5
High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients.大剂量静脉注射免疫球蛋白可能调节 COVID-19 患者的炎症。
Life Sci Alliance. 2021 Jul 28;4(9). doi: 10.26508/lsa.202001009. Print 2021 Sep.
6
Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review.静脉注射免疫球蛋白作为COVID-19的辅助治疗：一例病例报告及文献综述
SAGE Open Med Case Rep. 2021 Jun 30;9:2050313X211029699. doi: 10.1177/2050313X211029699. eCollection 2021.
7
Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model FcγRIIA and FcαRI.免疫调节：免疫球蛋白制剂在新冠病毒疾病模型中抑制过度炎症反应 FcγRIIA 和 FcαRI。
Front Immunol. 2021 Jun 10;12:700429. doi: 10.3389/fimmu.2021.700429. eCollection 2021.
8
Recent advances in antibody-based immunotherapy strategies for COVID-19.COVID-19 的抗体免疫疗法策略的最新进展。
J Cell Biochem. 2021 Oct;122(10):1389-1412. doi: 10.1002/jcb.30017. Epub 2021 Jun 23.
9
Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 - A theoretical perspective.静脉注射免疫球蛋白（IVIG）在调控危重症 COVID-19 炎症中的应用：理论视角。
Med Hypotheses. 2021 Jun;151:110592. doi: 10.1016/j.mehy.2021.110592. Epub 2021 Apr 9.
10
What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness.危重病与创伤科学有哪些新进展？静脉注射免疫球蛋白用于治疗重症或危重症 COVID-19。
Int J Crit Illn Inj Sci. 2020 Oct-Dec;10(4):159-162. doi: 10.4103/IJCIIS.IJCIIS_192_20. Epub 2020 Dec 29.
大剂量静脉注射免疫球蛋白作为新型冠状病毒肺炎病情恶化患者的一种治疗选择
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. doi: 10.1093/ofid/ofaa102. eCollection 2020 Mar.
4
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
6
A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.一种在中国出现的新型冠状病毒——影响评估的关键问题
N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24.
7
Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study.静脉注射免疫球蛋白与脓毒性休克肺炎患者的死亡率：一项全国性观察研究。
Clin Infect Dis. 2015 Aug 1;61(3):385-92. doi: 10.1093/cid/civ307. Epub 2015 Apr 16.
8
Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.静注人免疫球蛋白（pH4）治疗严重 2009 年甲型 H1N1 流感的多中心、双盲、随机对照临床研究
Chest. 2013 Aug;144(2):464-473. doi: 10.1378/chest.12-2907.
9
Immunoglobulin a modulates inflammatory responses in an in vitro model of pneumonia.免疫球蛋白A在肺炎体外模型中调节炎症反应。
J Trauma. 2005 Nov;59(5):1099-106. doi: 10.1097/01.ta.0000187797.38327.78.
10
Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency.静脉注射免疫球蛋白预防普通可变免疫缺陷患者肺炎的疗效
J Allergy Clin Immunol. 2002 Jun;109(6):1001-4. doi: 10.1067/mai.2002.124999.